EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

The PHOENYCS GO study reveals that dapirolizumab pegol, when combined with standard care, helps maintain disease control in systemic lupus erythematosus patients while reducing steroid use and flare rates over 48 weeks. This suggests a significant advancement in managing lupus, potentially lessening the long-term health risks associated with steroid treatment. The findings could offer a more sustainable treatment option for those living with the chronic condition, highlighting the drug's potential to improve quality of life for lupus patients.